Evidence map›Paper›PMID 38498565›Full record

ArticleThe Journal of infectious diseases2024

Outpatient Visits and Antibiotic Use Due to Higher-Valency Pneumococcal Vaccine Serotypes.

Laura M King, Kristin L Andrejko, Sarah Kabbani, Sara Y Tartof, Lauri A Hicks, Adam L Cohen, Miwako Kobayashi, Joseph A Lewnard

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Routine immunization againstThe Lancet regional health. Southeast Asia · 2024
    Article
  8. Upper respiratoryMicrobiology spectrum · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Laura M KingSchool of Public Health, University of California, Berkeley, California, USA.ORCID 0000-0002-7785-4712
Kristin L AndrejkoDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sarah KabbaniDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sara Y TartofDepartment of Research and Evaluation, Southern California, Kaiser Permanente, Pasadena, California, USA.ORCID 0000-0003-2336-8476
Lauri A HicksDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Adam L CohenDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Miwako KobayashiDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Joseph A LewnardSchool of Public Health, University of California, Berkeley, California, USA.
Centers for Disease Control and Prevention · USUniversity of California, Berkeley · USKaiser Permanente · US

Funding

Quantifying the impact of vaccines on antibiotic use for respiratory infections in childrenF31AI174773 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI KING, LAURA · 2023 to 2025
$90k
CDC HHS 21IPA2111845NIAID NIH HHS F31 AI174773NIH HHS 1F31AI174773-01
6 · The paper itself

Abstract

backgroundIn 2022-2023, 15- and 20-valent pneumococcal conjugate vaccines (PCV15/PCV20) were recommended for infants. We aimed to estimate the incidence of outpatient visits and antibiotic prescriptions in US children (≤17 years) from 2016-2019 for acute otitis media, pneumonia, and sinusitis associated with PCV15- and PCV20-additional (non-PCV13) serotypes to quantify PCV15/20 potential impacts.

methodsWe estimated the incidence of PCV15/20-additional serotype-attributable visits and antibiotic prescriptions as the product of all-cause incidence rates, derived from national health care surveys and MarketScan databases, and PCV15/20-additional serotype-attributable fractions. We estimated serotype-specific attributable fractions using modified vaccine-probe approaches incorporating incidence changes post-PCV13 and ratios of PCV13 versus PCV15/20 serotype frequencies, estimated through meta-analyses.

resultsPer 1000 children annually, PCV15-additional serotypes accounted for an estimated 2.7 (95% confidence interval, 1.8-3.9) visits and 2.4 (95% CI, 1.6-3.4) antibiotic prescriptions. PCV20-additional serotypes resulted in 15.0 (95% CI, 11.2-20.4) visits and 13.2 (95% CI, 9.9-18.0) antibiotic prescriptions annually per 1000 children. PCV15/20-additional serotypes account for 0.4% (95% CI, 0.2%-0.6%) and 2.1% (95% CI, 1.5%-3.0%) of pediatric outpatient antibiotic use.

conclusionsCompared with PCV15-additional serotypes, PCV20-additional serotypes account for > 5 times the burden of visits and antibiotic prescriptions. Higher-valency PCVs, especially PCV20, may contribute to preventing pediatric pneumococcal respiratory infections and antibiotic use.

Indexed as

Anti-Bacterial AgentsOtitis MediaPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeAdolescentAmbulatory CareChildChild, PreschoolFemaleHumansIncidenceInfantInfant, NewbornMaleAnti-Bacterial AgentsPneumococcal VaccinesVaccines, Conjugateacute otitis mediaantibioticoutpatientpediatricpneumococcal conjugate vaccinepneumoniasinusitisStreptococcus pneumoniae

Identifiers

PMID38498565
PMCPMC11481348
OpenAlexW4392900824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.